My bookmarksSign up free

Commission Implementing Decision (EU) 2026/1420 of 30 June 2026 on the non-approval of terbutryn, 1,2-Benzisothiazol-3(2H)-one (BIT) and tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) as existing active substances for use in biocidal products of product-types 9, 9, and 12, respectively, in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

Commission Implementing Decision (EU) 2026/1420 of 30 June 2026 on the non-approval of terbutryn, 1,2-Benzisothiazol-3(2H)-one (BIT) and tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) as existing active substances for use in biocidal products of product-types 9, 9, and 12, respectively, in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

Implementing Decision (EU) 2026/1420 · Decision · 3 articles

Data as of 2026-07-23 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

The active substances listed in the Annex are not approved as existing active substances for use in biocidal products of the product-types indicated therein.

Article 2

This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Supplementary provisions

ANNEXSupplementary provisions

ANNEX Active substance/product-type combinations not approved: Entry Number in Annex II to Regulation (EU) No 1062/2014 Substance name Rapporteur Member State EC number CAS number Product-type(s) 283 Terbutryn SK 212-950-5 886-50-0 9 339 1,2-Benzisothiazol-3(2H)-one (BIT) ES 220-120-9 2634-33-5 9 382 Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) ES 226-408-0 5395-50-6 12

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next